GlassScriptPhysician profile
Lisa G Keller
NPI 1205051562
$7,672.89
in general payments reported to CMS, 2019-2025
47 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,550 · 2022: $1,520 · 2023: $1,590 · 2024: $1,861 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,585 · Education: $18.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,584.50 |
| Education | $18.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.27 | 2021-2025 | |
| Amgen INC. | $630.26 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $582.77 | 2021-2025 | |
| Novo Nordisk INC | $456.05 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.85 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $410.85 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $363.03 | 2021-2025 | Airsupra, Breztri, Nexium |
| Glaxosmithkline, LLC. | $311.85 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $302.43 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $294.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $208.06 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Astellas Pharma US INC | $182.50 | 2021-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.32 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.77 | 2022-2025 | Xifaxan, Trulance |
| Eisai INC. | $121.41 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.